BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast CancerGlobeNewsWire · 3 days ago
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual MeetingGlobeNewsWire · Oct 6, 2026
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer StudyGlobeNewsWire · Sep 14, 2026
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer CenterGlobeNewsWire · Sep 8, 2026
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™GlobeNewsWire · Aug 24, 2026
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate CancerGlobeNewsWire · Aug 5, 2026BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.